Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18231882 | 0.86 | HTR2A (0.33) | HTR2AHTR2CHTR2BP2RX7 | |
| SCHEMBL19682452 | 0.82 | PKM (0.33) | PKMACHEP2RX7 | |
| SCHEMBL10472581 | 0.80 | TAAR1 (0.32) | — | |
| SCHEMBL12886698 | 0.79 | ACHE (0.33) | ENPP2PKMACHEP2RX7 | |
| SCHEMBL17997270 | 0.78 | ALDH1A1 (0.30) | — | |
| SCHEMBL2849049 | 0.77 | HTR2A (0.34) | ENPP2ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL1166843 | 0.77 | ENPP2 (0.33) | ENPP2ACHEP2RX7 | |
| SCHEMBL149090 | 0.77 | ACHE (0.32) | ENPP2ACHE | |
| SCHEMBL378747 | 0.77 | ACHE (0.32) | ENPP2ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL1561409 | 0.77 | TAAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| EP-2134691-B1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-25 | — | — | EP | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2134691-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ENPP2 1891/4885PKM 905/4885ACHE 4240/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ENPP2 1891/4885PKM 905/4885ACHE 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.